You are here

Press Release Archive

- Pfizer Recognized as Leader in Improving Climate Change for Second Consecutive Year

(BUSINESS WIRE)--Pfizer Inc announced today that for the second consecutive year it was recognized for its approach to improving the environment by being named to the Climate Disclosure Leadership Index (CDLI) by the Carbon Disclosure Project (CDP). The CDP is a not-for-profit coalition of 385 global investors with $57 trillion in assets under management. Pfizer was one of 383 Fortune 500 companies -- and one of nine in the chemical

- MannKind and Pfizer Announce Collaboration for Certain Exubera Patients to Transition to MannKind's Inhaled Insulin Therapy

(BUSINESS WIRE)--MannKind Corporation (Nasdaq: MNKD) and Pfizer Inc (NYSE: PFE) announced today that MannKind will transition certain Exubera patients with a continuing need for inhaled insulin to MannKind’s inhaled insulin product, Technosphere® Insulin. Technosphere Insulin is an investigational product that has recently completed Phase 3 clinical trials. In October 2007, Pfizer announced that it would

- Pfizer Launches New Medicine Safety Website to Help Healthcare Professionals and Patients Make Better Informed Decisions about Treatment Options

(BUSINESS WIRE)--Pfizer Inc announced today the launch of a new interactive online educational resource designed to give healthcare professionals, medical students, patients, patient advocates and the general public more information about medicine safety, and, in turn, more confidence when making decisions about appropriate treatment options. “We want to increase understanding of the industry’s system for ensuring

- Pfizer Oncology Presents Safety and Efficacy Results Of CP-751,871 Study At ESMO 2008

(BUSINESS WIRE)--Pfizer announced today updated safety and efficacy results surrounding its investigational compound, CP-751,871, in patients with non-small cell lung cancer (NSCLC). These results, along with supporting correlative science data, were presented at the 33rd European Society for Medical Oncology (ESMO) congress in Stockholm, Sweden. Results from a Phase II, randomized, non-comparative study, “Addition

- Pfizer Animal Health Adds Former Schering-Plough Products to European Portfolio

(BUSINESS WIRE)--Pfizer Animal Health today announced that its acquisition of multiple product franchises in Europe from the Schering-Plough Corporation has been completed and approved by the European Commission. Pfizer has acquired these assets for approximately euro 116 million in cash. The acquisition adds both biological and pharmaceutical products across the major animal health species including cattle, swine, equine and companion

- Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial

(BUSINESS WIRE)--Pfizer Inc today announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, including the U.S. new drug application (NDA) and the European marketing authorization application (MAA). Following feedback from regulatory authorities, the company plans to conduct an additional Phase 3 clinical trial with dalbavancin for the

- Data to Be Presented At ESMO 2008 Highlight Pfizer Commitment to Cancer Care and Research

(BUSINESS WIRE)--Pfizer announced today that important study results involving the company’s leading anticancer agent, SUTENT® (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12—16 September 2008. Researchers will present results of several analyses evaluating the cost

- Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Ian Read, President, Worldwide Pharmaceutical Operations, at the UBS Global Life Sciences Conference on Monday, September 22 at 2:00 p.m. Eastern Daylight Saving Time. To view and listen to the webcast, visit our web site homepage at and click on the “UBS Global Life Sciences Conference

- Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer's and Huntington's Diseases

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced today that they have entered into an agreement to develop and commercialize Dimebon, Medivation’s investigational drug for treatment of Alzheimer’s disease and Huntington’s disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial in patients with mild-to-moderate Alzheimer’s

- Lipitor 80 mg Provided Sustained Risk Reduction of Cardiovascular Events in Patients with Heart Disease During the Five-Year TNT Trial

(BUSINESS WIRE)--Pfizer announced that in patients with established heart disease, Lipitor® (atorvastatin calcium) 80 mg not only significantly reduced the relative risk of suffering a first cardiovascular event by 19 percent compared to Lipitor 10 mg but also provided a sustained reduction in the risk of a subsequent second, third, fourth, and fifth cardiovascular event, according to a subanalysis of the five-year Treating to New Targets

- Court in Denmark Upholds Two Lipitor Patents, Prevents Launch of Ranbaxy Generic Product before November 2011

(BUSINESS WIRE)--Pfizer Inc said today that the Eastern Division of the High Court in Copenhagen, Denmark has ruled in the company’s favor in challenges to two of its patents covering atorvastatin, the active ingredient in Lipitor. The basic (DK 171,588) and enantiomer (EP 409,281) patents were challenged by generics manufacturer Ranbaxy. The court ruled that the basic patent, which expires in November 2011, would be infringed

- Pfizer Says Vacation with Your Dog before the Summer Ends

(BUSINESS WIRE)--With canine motion sickness the leading reason pet owners are not able to take their dogs on day trips or vacation, Pfizer is encouraging more people to talk with their veterinarians about managing travel with their dog before the summer ends. Since Pfizer’s Cerenia™ (maropitant citrate) became the first-and-only veterinary approved canine medication in America, Europe and Canada to prevent vomiting from

- IAFF Launches Smoking Cessation Campaign with Pfizer

(BUSINESS WIRE)--The International Association of Fire Fighters has announced the launch of a new initiative to help fire fighters, family members and friends to quit smoking cigarettes. “Our goal is to help make the IAFF the first smoke-free union,” IAFF General President Harold Schaitberger said in his address to delegates at the IAFF 49th Convention. The IAFF is collaborating with pharmaceutical

- Lipitor 80 mg Reduced the Risk of Heart Attack and Stroke in Patients with Heart Disease, Type 2 Diabetes and Chronic Kidney Disease

(BUSINESS WIRE)--Pfizer Inc announced today that, in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor® (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 35 percent compared with Lipitor 10 mg. This finding is from a subanalysis designed and completed following the closure of the five-year Treating to New Targets (TNT) study in

- Pfizer Reports Second-Quarter 2008 Results

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE):                   ($ in millions, except per share amounts)    

- Pfizer to Showcase Alzheimer's Research and Pipeline at Upcoming Alzheimer's Disease Medical Meeting

BUSINESS WIRE)--Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer’s disease (AD) research and development program, including three on the two promising investigational therapies in the early stages of development, at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD) in Chicago, July 26-31. Pfizer will also host an analyst briefing at ICAD

- Pfizer Fully Supports Updated PhRMA Code

(BUSINESS WIRE)--Pfizer endorses the updates to the PhRMA Code on Interactions with Healthcare Professionals and will fully comply with all aspects of the Code. The updated PhRMA Code demonstrates Pfizer’s commitment to working with our customers in an open and responsible manner. Along with other member companies of PhRMA, we’ve updated the code to address the concerns of many of our stakeholders

- Patients More Likely to Stay on Lipitor Than Simvastatin, a Large Observational Study Shows

(BUSINESS WIRE)--Pfizer announced today that new statin users who took Lipitor® (atorvastatin calcium) were significantly more likely to stay on their medication compared to those who took simvastatin, according to an observational study of more than 186,000 patients in one of the largest U.S. managed care claims databases. The results were published in the July issue of Current Medical Research and Opinion. “It is


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.